Launch of the digestive enzyme Takadija-sterase® (1894, Meiji 27) – Dr. Takamune Kōmune discovered Takadija-sterase from koji mold
Released the digestive enzyme drug Takadijaester® (discovered by Dr. Kōfuku Yōkichi from koji mold)
Contributed to post‑war tuberculosis treatment with Sankyo’s chemotherapeutic agent Neoiskochin
Released the adrenal medullary hormone drug adrenaline (product name Adrenaline)
Sankyo’s first mass‑market health drug No. 1 – the popular capillary‑strengthening and blood‑flow‑improving drug Luchinon
Became Sankyo Co., Ltd.
The story of the world’s first antiplasmin agent Epsilon and its development
The achievements of the founders, the Shiohara couple, and the birth and growth of Sankyo’s flagship plant, the Shinagawa Factory
Dr. Umetaro Suzuki (1920, Taisho 9) became a scientific advisor to Sankyo and discovered the world’s first vitamin B1 (Oryzanin®) from rice bran, establishing the foundation of vitamin science
Manufacturing of the Japanese Harley “Rikuō” – Sankyo’s journey through import, sale, and domestic production of motorcycles during the Meiji, Taisho, and Showa eras
Dr. Umetaro Suzuki discovered vitamin B1 (Oryzanin®) from rice bran, establishing the foundation of vitamin theory
Started production of the first domestic synthetic pesticide, fumigant insecticide Kokuzōr
Dr. Umetaro Suzuki, who first discovered a vitamin worldwide, conducted research beyond his specialty and led many pharmaceutical successes
Featured in Natsume Sōseki’s “I Am a Cat”; the story of the birth of the stomach medicine Takadija-sterase
The origin of Daiichi Sankyo Europe – the company Luitpold & Welk
Founder of Daiichi Sankyo, Shiohara Masatsuke, and the tea room “Tengō-an” at the Tokyo National Museum
Founder of Daiichi Sankyo, Shiohara Masatsuke, and the tea room “Tengō-an” at the Tokyo National Museum
Post‑war drug development to save people from disease – the first domestic infection‑treatment drug and the pioneering tuberculosis treatment story
Delivering medicine even in difficult times – the birth and growth of the four Sankyo factories
Founder of Daiichi Sankyo, Shiohara Masatsuke, and the tea room “Tengō-an” at the Tokyo National Museum
Early adoption of the American pharmacy model – the Marunouchi Sankyo Pharmacy with a soda fountain café
Selling medicine in an advanced wooden Western‑style building – Sankyo’s exclusive product at the Nihonbashi “Chūō Pharmacy”
For increased production of Salvarsan and new drug manufacturing. The secret story of the birth of the mythical "Second Pharmaceutical"
The expansion into East Asia led by the third president of Daiichi Sankyo, Tokuzo Shiohara
Developed a drug available to the general public. Comprehensive vitamin supplement "Vitabea"
Long‑selling "Lulu" and its evolution history
Founder of Sankyo, Masatsugu Shiohara, and the tea room "Tengou-an" preserved at the Tokyo National Museum
Founder of Daiichi Sankyo, Masatsugu Shiohara, and the tea room "Tengou-an" preserved at the Tokyo National Museum
Released the analgesic and anti‑inflammatory drug Loxonin®
Opened the Komiyama plant
Released the mini‑drink solution Reign®
Released the globally groundbreaking high‑cholesterol‑lowering drug Mebarotin®
Released the antibiotic formulation Banann®
Invested in the Luitpold & Welk Group
Received the Daikawachi Memorial Production Award for developing the hyperlipidemia drug Pravastatin (product name Mebarotin®)
Completed the former headquarters building in Tokyo Nihonbashi
Established Sankyo Pharma Inc. (New Jersey, USA)
Koyanohama and Odawara factories obtained ISO14001 certification for the first time as a Japanese pharmaceutical company
Released the blood glucose-lowering drug Fastic®
Released the global blood pressure-lowering drug Olmesartan in the United States and Germany (product name Benicar® in the United States, Olmetec® in Germany)
Released the sustained-release calcium channel blocker (blood pressure-lowering drug) Carblock®
Released the global blood pressure-lowering drug Olmesartan in Japan (product name Ormetec®)
Astellas donated to the Ministry of Health, Labour and Welfare's "Innovative Pharmaceutical and Related Products Utilization Support Fund". This fund aims to support the development and commercialization of drug discovery seeds and to promote the development of Japan's drug discovery ecosystem. Through early-stage support, Astellas contributes to accelerating the supply of medicines to patients.
Daiichi Sankyo took part in Girls Meet STEM, a program run by the Shinjiro Yamada D&I Foundation, and held office tours for junior and senior high school girls. The first tour was at the Shinagawa R&D Center and the second at the Nihonbashi headquarters. A total of 66 students attended, and female employees in research and pharmacovigilance spoke about their work. Students experienced real work environments and were encouraged to explore science-related fields.
American Regent has obtained ISO 14001:2015 and ISO 45001:2018 certification at all of its U.S. sites in Shirley, Ohio, and Blair, as well as its site in Altkirch, France. This completes certification at all Daiichi Sankyo Group plants and strengthens integrated environmental management and occupational health and safety systems to help protect employees’ safety and health.
Daiichi Sankyo Co., Ltd. will donate ¥5 million to Japan Platform’s relief efforts for victims of landslides in central Nepal following flooding and landslides near the Nepal–China border. The company hopes the affected areas will recover and rebuild promptly.
Daiichi Sankyo Company, Limited was selected as a constituent of the JPX-Nikkei Index Human Capital 100 for the one-year period beginning August 31, 2026. The index selects the top 100 companies based on assessments of human capital initiatives from among constituents of the JPX-Nikkei Index 400. Daiichi Sankyo will continue to create an environment where diverse talent can thrive and make strategic personnel assignments to enhance corporate value.
Daiichi Sankyo Company, Limited has disclosed payments made in fiscal 2024 to medical institutions and patient organizations in accordance with the transparency guidelines of the Japan Pharmaceutical Manufacturers Association and related organizations. See the official website for details.
Daiichi Sankyo's next-generation support program provides grants to cancer and intractable-disease patient groups and support organizations to strengthen their sustainability. In the third round for fiscal 2026, nine organizations were selected to receive a total of ¥7,079,950. Eligible projects include developing the next generation of leaders, improving care environments and supporting employment.
Daiichi Sankyo Company, Limited donated ¥3 million to the Japanese Red Cross Society to support people affected by the heavy rains in Chiba in August 2026. The company hopes for a swift recovery and reconstruction of the affected areas.
Daiichi Sankyo Co., Ltd. and Plan International Japan launched a project in Paraguay in April 2026 to prevent cervical cancer and promote young people's health, rights, and access to care. Cervical cancer is the leading cause of cancer death among women in Paraguay, while regional disparities and limited information make prevention and early detection difficult.
Daiichi Sankyo Co., Ltd. has donated 20 million yen to the Japanese Red Cross Society for those affected by the Kumamoto Earthquake in Reiwa 8. We hope for the early recovery and reconstruction of the disaster area.